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Center for Cancer Research, National Institutes of Health, Bethesda, MD, United StatesT memory stem cells (TSCM), a rare subset of memory lymphocytes
endowed with enhanced capacity of self-renewal and the potential to
reconstitute the full repertoire of memory and effector cells, have re-
cently emerged as a central player in several physiological and patho-
logical processes. TSCM cells have been shown to mediate superior
anti-tumor responses (Gattinoni et al., 2009, Gattinoni et al., 2011),
harbor leukemic cancer stem cells (Nagai et al., 2015), and serve as a
reservoir for HIV infection (Buzon et al., 2014). Because of these wide-
ranging clinical implications, it is of critical importance to improve our
understanding of the molecular events that induce or maintain TSCM
cells.
In this issue of EBiomedicine, Scholz et al. used pharmacological and
genetic approaches to identify mTOR as a key signaling pathway regu-
lating the formation of CD4+ and CD8+ TSCM cells (Scholz et al., 2016).
It has previously been demonstrated in murine (Gattinoni et al., 2009)
and human (Gattinoni et al., 2011) models that the formation of TSCM
cells can be promoted by triggeringWNT/β-catenin signaling. The ﬁnd-
ing that inhibition of themTORpathway can also favor the generation of
TSCM cells has signiﬁcant therapeutic implications as rapamycin and
other mTOR inhibitors are FDA-approved agents that have already
been used in T cell adoptive therapy clinical trials (clinicaltrials.gov.;
NCT00074490, NCT01239368). As such, the contribution of Scholz
et al. may accelerate the ﬁeld in terms of bringing TSCM cells into the
clinical arena.
TSCM cells are an ideal cell population to employ in T cell-based im-
munotherapies because of their enhanced capacity to engraft and ability
to persist for the long-term. Using a human-into-mouse xenogeneic
transplantation model, the authors found that TSCM cells manufactured
in rapamycin had increased persistence relative to control naïve or
central-memory T cells, recapitulating prior observations obtained
using naturally occurring TSCM cell populations (Gattinoni et al., 2011).
These ﬁndings are also consistent with a body of literature indicating
that rapamycin-resistant human Th1/Tc1 cells have a remarkable ability
to repopulate xenogeneic hosts and mediate graft-versus-host disease
effects (Amarnath et al., 2010). Additional in vivo functional endpoints,
however, will be needed to determine the therapeutic potential of the
rapamycin-generated TSCM cell populations as manufactured by Scholz
et al.DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.01.019.
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metabolism for immunotherapeutic interventions as it has become
clear that metabolism can profoundly inﬂuence T cell functionality
and fate commitment. Up to this point, the metabolic proﬁle of TSCM
cells has remained elusive. Now, Scholz et al. shed new light on the
metabolic regulation of human CD4+ TSCM cells and have revealed
that, similar to naïve and memory T cell populations, TSCM cells rely on
fatty acid oxidation as a primary source for ATP synthesis. These ﬁnd-
ings are fundamental because they open up the possibility to promote
the formation and maintenance of TSCM cells through the manipulation
of fatty acid metabolism.
While underlying a central role for mTOR in the generation of TSCM
cells, Scholz et al. dispute a role for WNT/β-catenin signaling. The au-
thors argue that theWNT activator, TWS119, promoted TSCM cell gener-
ation not by the conventionally recognized mechanism (GSK3β
inhibition and subsequent β-catenin stabilization) but rather via an
off-target effect that involved mTOR inhibition; their conclusion was
based in part on their observations that neither a physiological
WNT3A ligand nor alternative GSK3β inhibitors supported TSCM forma-
tion in their hands. However, the authors used WNT3A at concentra-
tions 100-fold lower than those used in previous studies that found an
active role of WNT3A in the generation of both murine and human
TSCM cells (Gattinoni et al., 2009, Muralidharan et al., 2011). In their ex-
periments, the lack of activity of the GSK3β antagonist indirubin-3-
monoxime was potentially attributable to its weak selectivity and in-
ability to trigger downstream WNT signals (Meijer et al., 2003). In
sharp contrast, the highly selective, 6-bromoinduribin derivatives,
which are capable of stabilizing β-catenin (Meijer et al., 2003), have
successfully been employed to generate TSCM cells (Gattinoni et al.,
2009). It is also important to underscore that the authors did not pro-
vide evidence of the ability of these ‘ineffective’ agents to activate
WNT/β-catenin signaling. Indeed, Scholz et al. employed as a WNT op-
erational readout the phosphorylation of GSK3β serine 9, a post-transla-
tional modiﬁcationmediated by AKT and not involved inWNT signaling
(McManus et al., 2005) (gold standard assayswould consist ofmeasure-
ment of unphosphorylated β-catenin and WNT-reporter activity). In a
ﬁnal attempt to support their conclusion of TWS119 action outside of
the GSK3β/WNT pathway realm, the authors used an elegant model in-
volving β- and γ-catenin deﬁcient T cells. However, conclusions based
on these experiments carry themajor caveat thatWNT signal transmis-
sion is substantially maintained in double-deﬁcient T cells (Jeannetense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
4 D.H. Fowler, L. Gattinoni / EBioMedicine 4 (2016) 3–4et al., 2008). Further research will therefore be required to more deﬁn-
itively test the extent to which GSK3β inhibitors such as TWS119might
mediate their effect on TSCM cells independent of the WNT pathway.
In summary, Scholz et al. have tackled a critical issue in biomedicine
relating to human CD4+ and CD8+ T memory stem cell generation and
function. Although the molecular mechanism(s) of TSCM cell generation
remain nebulous vis-à-vis the relative role of WNT/β-catenin or mTOR
modulation, the current report certainly provides a nidus of information
that will guide subsequent investigations. Hopefully, with the attain-
ment of a reﬁned molecular understanding and the development of
alternative pharmacologic inhibitors, an ability to effectively modulate
TSCM cells for therapeutic purposes will be realized.
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